期刊文献+

安托可金(0325k_(1-1)在大鼠体内的药代动力学 被引量:8

The Pharmacokineticsof0325k_(1-1) in Rats
下载PDF
导出
摘要 以原子吸收法测定了大鼠血浆、组织与胆汁、尿、粪便中安托可金的浓度。大鼠静注安托可金后符合二房室模型处置特征 ,分布半衰期平均为 0 .2 5± 0 .0 2h ,消除半衰期平均为 1 1 .4± 0 .57h ,中央室分布容积为 0 .1 6± 0 .0 5L/kg。静注安托可金后该药可很快向机体的各组织分布 ,大多数组织在 6min即达到较高浓度 ;其中以肾脏浓度最高 ,肝、肺、子宫、皮肤、瘤体等组织也有较高的浓度。静注给药后 ,2 4h的累积尿排泄率平均为 (77.6± 1 0 .3 ) % ,1 2 0h的累积排泄率平均为 (90 .7± 3 .80 ) % ,说明肾脏是该药的主要排泄途径 ;安托可金在粪中的排泄较少 ,1 2 0h的累积排泄率平均为 (2 .87± 0 .4 6) % ,2 4h的胆汁累积排泄率平均为(1 .0 1± 0 .2 9) % ,说明粪和胆汁不是该药的主要排泄途径。安托可金与大鼠的血浆蛋白结合率平均为 (4 0 .7± 3 .4 9) %。 The concentration of 0325k 1 1 in the plasma,tissues, bile, urine and faeces of rats has been determined by flameless atomic absorption spectrophotometry. The plasma concentration time profiles fitted to two compartments after i.v., and the distribution half life t 1/2α was 0.25±0.02 h and the elimination half life t 1/2β was 11.4±0.57 h and the distribution volume of central compartment V c was 0.16±0.05 l/kg. The distribution process of 0325k 1 1 to tissues was much quicker, and the levels at 6 min was the highest for most tissues after iv use. For all tissues studied, the kidney, liver, lung, skin and tumor tissues had higher levels than those of other tissues. More than 90% of the drug was excreted in urine after i.v. but less than 3% was found in bile or faeces. The combination rate of the drug to plasma protein was (40.7±3.49)%.
出处 《中国药科大学学报》 CAS CSCD 北大核心 2000年第1期56-60,共5页 Journal of China Pharmaceutical University
关键词 安托可金 药代动力学 抗肿瘤药 K_(1-1) Platinum Atom absorption spectrophotometry Tisue distribution Pharmacokinetics
  • 相关文献

参考文献15

二级参考文献97

共引文献397

同被引文献19

  • 1李文钧,郑永兴.石墨炉原子吸收法测定体内顺铂[J].药物分析杂志,1989,9(2):82-85. 被引量:10
  • 2王娟,马淑清,云佩茹,郭连兴,王晓斌,陈峻青.碳铂腹腔给药HPLC测定法及犬的药代动力学研究[J].实用肿瘤学杂志,1997,11(1):4-6. 被引量:4
  • 3黄卫平,刘放.RP-HPLC法测定卡铂及其制剂的含量[J].华西药学杂志,1997,12(2):112-114. 被引量:6
  • 4Kawabata Y,Nakamura H,and Kamada E,et al.Mechanism of hepatobiliary transport of a novel thromboxane A2 receptor antagonist,[2-(4-chlorophenylsulfonylaminomethyl)indan-5-yl]acetate(Z-335),and its xenobiotic taurine conjugate(Z-335-Tau)in rats.J Pharm Sci,2003,92(1):67-76.
  • 5Adnan EY, Iman AS. Rapid determination of platinum by flameless atomic absorption spectrophotometry following the administration of cisplatin to cancer patients[J]. Thererapeutic Drug Monitoring, 1986,8:318-320.
  • 6Kawabata Y,Nakamura H,Kamada E,et al.Mechanism of hepato-biliary transport of a novel thromboxane A2 receptor antagonist,[2-(4-chlorophenylsulfonylaminomethyl) indan-5-yl]acetate (Z-335),and its xenobiotic taurine conjugate (Z-335-Tau) in rats[J].J Pharm Sci,2003,92(1):67 -76.
  • 7Safirstein R,Winston J,Moel D,et al.Cisplatin nephrotoxicity:insights into mechanism[J].Int J Androl,1987,10 (1):325~346.
  • 8Li Q,Bowmer CJ,Yates MS.The protective effect of glycine in cisplatin nephrotoxicity:hibition with NG-nitro-L-arginine methyl ester[J].Pharm Pharmacol,1994,6 (5):346 ~ 351.
  • 9李秀琴,陈西敬,任伟超,张辉,顾萱.大鼠静脉注射3种铂制剂后铂的肾排泄与肾分布比较研究[J].中国药房,2008,19(28):2187-2188. 被引量:4
  • 10谢瑞祥,吴国森,林川,朱世权,范芳.HPLC法测定人血清卡铂浓度[J].海峡药学,1999,11(1):41-42. 被引量:2

引证文献8

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部